Abbott Laboratories legal and compliance interviews test whether candidates understand how in-house legal practice at a diversified healthcare company operating across medical devices, diagnostics, pharmaceuticals, and nutritionals differs from legal practice at a single-segment healthcare company – where the FDA regulatory framework creates different legal obligations for each of Abbott's four product categories (medical devices require 510(k) clearance or PMA approval, in vitro diagnostics have separate IVD regulatory pathways, pharmaceuticals require NDA or ANDA approval, and food products including infant formula require different FDA oversight than drugs or devices), where the FreeStyle Libre CGM creates a digital health and connected device legal framework that encompasses data privacy under HIPAA, cybersecurity requirements for FDA-regulated software as a medical device, and the emerging regulatory obligations for artificial intelligence in diabetes management tools, where the federal anti-kickback statute and related laws create commercial compliance obligations for Abbott's device and diagnostic sales forces whose customer interactions with physicians and hospital purchasing organizations must be managed within specific safe harbors, and where Abbott's global operations across more than 160 countries create an international regulatory and compliance portfolio spanning FDA, CE marking under MDR and IVDR in Europe, PMDA in Japan, CDSCO in India, and hundreds of additional country regulatory agencies. Legal and compliance at Abbott spans medical device regulatory compliance and FDA enforcement response (where managing 510(k) submissions, IDE trials, PMA applications, and post-market surveillance obligations for the FreeStyle Libre, structural heart, and diagnostics portfolio requires regulatory counsel who understand both the pre-market approval pathway and the post-market safety reporting obligations that define Abbott's ongoing FDA relationship), healthcare fraud and abuse compliance for commercial operations (where the anti-kickback statute, Stark Law, and False Claims Act create commercial compliance frameworks for device and diagnostic sales that must permit legitimate educational, research, and customer service activities while preventing arrangements that could constitute illegal remuneration), digital health and connected device regulatory compliance (where the FDA's regulatory framework for software as a medical device, the FCC requirements for wireless medical device communication, and HIPAA's privacy requirements for connected glucose monitoring data create an overlapping regulatory framework for FreeStyle Libre's connected capabilities), and international regulatory strategy and compliance coordination (where the EU Medical Device Regulation's Article 10 requirements for quality management systems, clinical evidence requirements for CE marking, and Notified Body audit management create European compliance obligations that parallel but differ from FDA requirements in ways that create international regulatory strategy decisions for each device family).
Start your free Abbott Laboratories Legal & Compliance practice session.
What interviewers actually evaluate
FDA Regulatory Strategy, Anti-Kickback Commercial Compliance, and Digital Health Legal Framework
Abbott legal and compliance interviews probe whether candidates understand how healthcare regulatory compliance at a diversified medical technology and consumer health company differs from compliance at a single-segment company in the multi-regulatory-framework navigation requirement (Abbott's products span the FDA's four primary regulatory frameworks – medical devices, in vitro diagnostics, human drugs, and food – and legal professionals who understand how these frameworks create different pre-market approval requirements, post-market surveillance obligations, and marketing restriction frameworks for each product category will provide more useful regulatory counsel than those who apply a single regulatory framework to all of Abbott's products), the healthcare commercial compliance sophistication requirement (the anti-kickback statute's framework for medical device and diagnostic commercial activities – including the breadth of permissible educational programs, research support, and customer service activities versus prohibited arrangements that create remuneration designed to induce referrals – requires compliance professionals who understand both the legal safe harbors and the practical commercial context in which Abbott's device and diagnostic sales teams operate, because compliance programs that are overly restrictive will impair legitimate commercial relationships while those that are insufficiently rigorous create enforcement risk), and the digital health emerging regulatory landscape (FreeStyle Libre's connectivity – sensor to smartphone to caregiver app to insulin delivery device – creates a digital health regulatory environment where FDA guidance on software as a medical device, interoperability, and AI/ML-based clinical decision support is actively evolving, and legal professionals who track these regulatory developments and advise Abbott's digital product teams on their compliance implications will prevent products from reaching market with unaddressed regulatory gaps).
The Similac regulatory enforcement response dimension requires understanding that Abbott's 2022 Sturgis facility shutdown and the subsequent FDA consent decree for infant formula manufacturing created a regulatory enforcement relationship management challenge that required legal teams to coordinate production restart negotiations, FDA inspection response, and regulatory disclosure obligations while managing the company's public communication and consumer safety response simultaneously.
What gets scored in every session
Specific, sentence-level feedback.
| Dimension | What it measures | How to answer |
|---|---|---|
| FDA device regulatory pathway strategy | Do you understand how to advise Abbott's device product teams on FDA regulatory strategy – how to assess whether a FreeStyle Libre product iteration (such as a new sensor generation with a different measurement algorithm) requires a new 510(k) submission versus can be handled as a design change under the existing clearance, what the timeline and evidentiary requirements look like for a De Novo classification request for a novel device type, and how to advise on the risk of 510(k) versus PMA pathway selection for structural heart devices where the PMA pathway provides stronger market exclusivity but at longer timeline and higher evidentiary cost? We flag legal answers that describe FDA clearance as a paperwork process without engaging with the strategic pathway selection and product development regulatory integration that determines how efficiently Abbott's device portfolio reaches market. | 510(k) vs PMA pathway selection framework for device regulatory strategy, design change versus new submission determination for product iteration, De Novo classification criteria for novel device types |
| Anti-kickback commercial compliance program design | Can you describe how to design the anti-kickback compliance program for Abbott's medical device and diagnostic sales forces – how to define the permissible scope of physician educational programs, advisory board participation, and customer training that can be funded by Abbott without creating AKS exposure, what the monitoring controls look like for identifying commercial arrangements that may create prohibited remuneration risk, and how to design compliance training that helps sales representatives distinguish between legitimate consultative customer relationships and arrangements that create compliance risk? We score whether your AKS compliance approach engages with the commercial activities specificity and safe harbor analysis that distinguish sophisticated healthcare commercial compliance from generic ethics training. | Permissible educational program design within AKS safe harbors for medical device sales, advisory board and consulting arrangement compliance criteria, monitoring controls for identifying potentially impermissible commercial arrangements |
| Digital health and connected device regulatory compliance | Do you understand how to advise FreeStyle Libre's digital product team on the regulatory framework for connected CGM – how to determine which software functions constitute a software as a medical device (SaMD) requiring FDA oversight versus administrative software that falls outside FDA's software regulation, what the FDA's risk-based SaMD classification criteria require for the LibreLink smartphone app and LibreLinkUp caregiver sharing feature, and how HIPAA's definition of protected health information applies to glucose data stored in Abbott's cloud infrastructure? We detect legal answers that describe digital health compliance as general privacy law without engaging with the FDA SaMD framework and medical device data HIPAA intersection that are specific to connected CGM compliance. | FDA SaMD classification for CGM smartphone app and data sharing features, HIPAA PHI analysis for glucose monitoring data in cloud infrastructure, cybersecurity requirements for connected medical device regulatory submissions |
| International regulatory compliance and EU MDR strategy | Can you describe how to manage Abbott's EU Medical Device Regulation compliance transition – how the Article 10 QMS requirements differ from the previous Medical Device Directive requirements in ways that require documentation updates, what the clinical evidence requirements for CE marking under MDR require for devices that had historical clinical data under the MDD, and how to manage the Notified Body audit timeline in an environment where Notified Body capacity constraints have created certification backlogs that affect device market access timelines in EU member states? We flag legal answers that describe international device compliance as jurisdiction-by-jurisdiction country registration without engaging with the EU MDR's systematic quality and clinical evidence framework that requires planned compliance investment. | EU MDR Article 10 QMS requirements versus MDD transition gap analysis, clinical evidence requirements under MDR for legacy MDDcleared devices, Notified Body audit planning under MDR certification timeline constraints |
How a session works
Step 1: Choose an Abbott Laboratories legal and compliance scenario – FDA device regulatory pathway strategy, anti-kickback commercial compliance program design, digital health and connected device regulatory compliance, or international regulatory compliance and EU MDR strategy.
Step 2: The AI interviewer asks realistic Abbott legal and compliance questions: how you would advise the FreeStyle Libre product team on whether a new sensor generation with a modified glucose measurement algorithm requires a new 510(k) submission or can be implemented under the existing device clearance as a design change, including what predicate device analysis and clinical performance data would be required to support a substantial equivalence determination; how you would design the compliance review process for a proposal by Abbott's hospital diagnostics sales team to provide complimentary Alinity analyzer placements (instruments provided at no cost in exchange for reagent purchase commitments) in competitive displacement situations, including what AKS framework applies to diagnostic instrument placements and what the compliance conditions are for a defensible arrangement; or how you would advise Abbott's digital health team on the regulatory classification of the FreeStyle Libre predictive alert feature that uses AI to predict a future low glucose event 60 minutes before it occurs, including whether this feature constitutes a clinical decision support software or a SaMD requiring FDA clearance.
Step 3: You respond as you would in the actual interview. The system scores your answer on FDA regulatory strategy, anti-kickback compliance design, digital health regulatory framework, and EU MDR compliance.
Step 4: You get sentence-level feedback on what demonstrated genuine Abbott diversified healthcare legal expertise and what needs stronger FDA SaMD classification specificity or AKS commercial compliance safe harbor analysis.
Frequently Asked Questions
How does FDA regulate Abbott's four product categories differently?
Abbott's FreeStyle Libre CGM is regulated as a Class II medical device requiring 510(k) clearance (most generations) or De Novo classification for novel features. Abbott's Alinity in vitro diagnostic analyzers are regulated under FDA's IVD framework, which applies to laboratory instruments and reagents differently from therapeutic devices. Abbott's Established Pharmaceuticals products are regulated as drugs requiring NDA, ANDA, or foreign-approved equivalents. Abbott's nutritional products (Ensure, Similac) are regulated as foods under FDA's food safety framework, including the infant formula manufacturing standards under 21 CFR Part 106 that became the focus of FDA enforcement at the Sturgis facility. Each framework has different pre-market requirements, manufacturing standards (GMP requirements differ between devices, drugs, and foods), and post-market reporting obligations.
What is the anti-kickback statute and how does it apply to medical device sales?
The federal anti-kickback statute prohibits knowingly offering, paying, soliciting, or receiving remuneration to induce or reward referrals of items or services covered by federal healthcare programs. For medical device companies like Abbott, it applies to commercial activities with physicians, hospitals, and other healthcare providers who make purchasing or referral decisions about Abbott's products. Permissible activities under statutory safe harbors include bona fide consulting agreements at fair market value, training programs that educate on device use, and equipment or service arrangements structured to reflect market value. Activities that provide value beyond fair market value in ways designed to influence purchasing decisions create AKS risk. Abbott's commercial compliance program must define the permissible scope of speaker programs, advisory boards, and research support for device and diagnostic categories.
How does HIPAA apply to FreeStyle Libre's connected features?
FreeStyle Libre's connected ecosystem – including the LibreLink smartphone app that reads sensor glucose data, the LibreLinkUp app that allows caregivers to view a patient's glucose readings, and the Abbott cloud infrastructure that stores and processes glucose data – creates HIPAA compliance obligations because glucose readings combined with patient identifiers constitute protected health information. Abbott's compliance obligations depend on whether it is acting as a covered entity (when patients use Abbott's own app and cloud services directly) or as a business associate (when it processes patient data on behalf of a covered entity healthcare provider). The evolving digital health regulatory environment also requires Abbott to address FDA cybersecurity guidance requirements for networked medical devices in its Libre regulatory submissions.
What is the EU Medical Device Regulation and why is it significant for Abbott?
The EU Medical Device Regulation (MDR, Regulation 2017/745) replaced the prior Medical Device Directive (MDD) with more stringent requirements for device certification in the European Union. Key changes include stricter clinical evidence requirements (requiring clinical data to be generated on the specific device rather than demonstrating equivalence to a predicate), enhanced post-market surveillance obligations, and more rigorous quality management system requirements under Article 10. Abbott's device portfolio – including FreeStyle Libre, Alinity, and structural heart products – required significant compliance investment to achieve MDR certification for continued EU market access. Notified Body capacity constraints created certification bottlenecks that affected Abbott's ability to certify new product generations in the EU on the timeline it planned.
How does Abbott manage FCPA compliance for its global commercial operations?
Abbott's global presence across more than 160 countries, including many where Abbott's Established Pharmaceuticals segment operates in healthcare environments with significant corruption risk, creates Foreign Corrupt Practices Act compliance obligations for commercial interactions with government-owned hospitals, publicly employed physicians, and government regulatory agencies. Abbott's FCPA compliance program addresses payments, gifts, travel, and entertainment involving government-connected healthcare customers in jurisdictions with elevated bribery risk. The Established Pharmaceuticals segment, which sells in markets including India, Latin America, and Southeast Asia where government-owned healthcare facilities are common, requires particularly rigorous FCPA compliance training and monitoring given the frequency of commercial interactions with government-employed healthcare professionals.
Also practice
One full session free. No account required. Real, specific feedback.
